TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02536768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimum package of interventions to improve ART adherence
Description: Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
Study: NCT02349399

Intervention type: DRUG
Intervention: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
Description: Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
Study: NCT00382720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Oxaliplatin
Description: Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Oxaliplatin + 5-FU
Description: Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Oxaliplatin + Capecitabine
Description: Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.
Study: NCT01508104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: dose escalation 400mg- 1000mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: dose escalation 2.5 to 5 mg per day
Study: NCT03377842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib and FOLFOX regimen
Description: Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
Study: NCT00829049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream 0.1%
Description: 1 pea-size amount, QD x 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: 1 pea-size amount, QD x 16 weeks
Study: NCT01819649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Study: NCT00880659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soap
Description: Promotion of handwashing with soap
Study: NCT00182832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)
Description: Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care for hospitalized older patients with cognitive impairment
Study: NCT00993642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
Study: NCT00761306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 5 or 10 mg/day; tablets; orally
Study: NCT01524198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: 500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
Study: NCT02142738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed Lyophilized Powder for Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed Lyophilized Powder for Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed Lyophilized Powder for Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine Lyophilized Powder for Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine Lyophilized Powder for Infusion
Study: NCT04737408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40mg
Description: Rosuvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg
Description: Rosuvastatin 40 mg
Study: NCT00356083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study: NCT02742597

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIP / IMPACT Plus Care Coordination
Description: The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIP / IMPACT Plus Care Coordination
Description: The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
Study: NCT01094587

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroschisis closure with suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroschisis closure without suture
Study: NCT03540225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
Study: NCT02524522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTELLiVENT-ASV mode
Description: Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMV mode
Description: Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
Study: NCT04296877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily Disposable Contact Lens
Description: Soft, daily disposable spherical contact lens used to correct distance vision.
Study: NCT02005991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
Study: NCT03361150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIT
Description: Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
Study: NCT04002037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg/ml
Description: Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
Study: NCT03921320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral sequential sympathectomy
Description: Bilateral videothoracoscopic sequential R4 sympathectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral sympathectomy
Description: Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contralateral sympathectomy
Description: Contralateral (left side) videothoracoscopic R4 sympathectomy
Study: NCT04183816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total cold-water immersion
Description: TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice massage
Description: Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
Study: NCT02408705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance Test with paracetamol
Description: At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Meal Tolerance Test with paracetamol
Description: At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
Study: NCT00750698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
Study: NCT04144270

Intervention type: OTHER
Intervention: Evaluation of muscle mass and muscle function
Description: Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
Study: NCT03040791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study: NCT01434420

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRCA1 BRCA2 PTEN PALB2 mutation
Description: detection of BRCA1 BRCA2 PTEN PALB2 mutation
Study: NCT04467944

Intervention type: OTHER
Intervention: Pre-existing degenerative factors at adjacent segment
Description: Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors

Intervention type: OTHER
Intervention: Pre-existing degenerative factors at adjacent segment
Description: Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
Study: NCT00542464

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
Study: NCT02071212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Loading dose 180 mg . Maintainance dose 90 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Loading dose 180 mg . Maintainance dose 90 mg BID
Study: NCT00710879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multi-Purpose Solution
Description: Daily care for contact lenses.
Study: NCT01519804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onartuzumab
Description: 15 mg/kg iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
Study: NCT03143010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal Dexmedetomidine
Description: injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 micrograms
Description: injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3 micrograms
Description: injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 micrograms
Description: injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
Study: NCT03887533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
Study: NCT03378804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus application (PIEB)
Description: Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continous epidural analgesia
Study: NCT02430142

Intervention type: OTHER
Intervention: Vasoocclusive testing
Description: Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;

Intervention type: OTHER
Intervention: Vasoocclusive testing
Description: Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;

Intervention type: OTHER
Intervention: Vasoocclusive testing
Description: Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
Study: NCT01841502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: paroxetine 20 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: paroxetine 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: telaprevir 1125 mg twice daily
Study: NCT04106882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketones
Description: Supplement administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketones
Description: Supplement administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement administered mid-scan.
Study: NCT06397755

Intervention type: PROCEDURE
Intervention: Prostate Biopsy and/or Radical Prostatectomy
Description: Prostate Biopsy: procedure to remove samples of suspicious tissue from the prostate Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
Study: NCT04368572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase
Study: NCT01858532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT02080442

Intervention type: OTHER
Intervention: Balance training
Description: Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.